FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200221566> ?p ?o ?g. }

• W4200221566 abstract "Aim: The aim of present study is to evaluate the diagnostic and prognostic value of plasma galectin 3 (Gal-3) for HF originating from different causes. Methods: We investigated the plasma levels and expression of Gal-3 in cardiac tissues in two transgenic (TG) strains of mice with cardiomyocyte-restricted overexpression of either β2- adrenergic receptor (β2- AR TG) or Mammalian sterile 20-like kinase 1 (Mst1-TG) in the present study. Additionally, 166 patients suffering from heart failure with reduced ejection fraction (HFrEF) in two hospitals within the Shaanxi province were examined in this study. All these patients were treated according to the Chinese HF guidelines of 2014; subsequently, they were followed up for 50 months, and we analyzed the prediction value of baseline Gal-3 to endpoints in these patients. Results: Gal-3 was localized in the cytoplasm and nucleus of cardiomyocytes, often formed aggregates in Mst1-TG mice. Extracellular Gal-3 staining was uncommon in Mst1-TG hearts. However, in β2-AR TG mice, although Gal-3 was also expressed in myocardial cells, it was more highly expressed in interstitial cells (e.g., fibroblasts and macrophages). Plasma Gal-3 was comparable between nTG and Mst1-TG mice. However, plasma Gal-3 was higher in β2-AR TG mice than in nTG mice. In the cohort of HFrEF patients, the median plasma Gal-3 concentration was 158.42 pg/mL. All participants were divided into two groups according to Gal-3 levels. Patients with Gal-3 concentrations above the median were older, and had lower plasma hemoglobin, but higher plasma creatinine, tissue inhibitor of metalloproteinases 1 (TIMP-1), left ventricular end systolic diameter (LVESD), left ventricular end-systolic volumes (LVESV) and end-diastolic, as well as left ventricular end-diastolic volumes (LVEDV). Spearman correlation analysis revealed that Gal-3 was positively correlated with TIMP-1 (r = 0.396, P < 0.001), LVESV (r = 0.181, P = 0.020) and LVEDV (r = 0.190, P = 0.015). The 50-month clinical follow-up revealed 43 deaths, 97 unplanned re-hospitalizations, and 111 composite endpoint events. Cox analysis demonstrated that although Gal-3 did not provide any prognostic value in either total-HF subjects or coronary-heart-disease (CHD) patients, it did provide prognostic value in non-CHD patients. Conclusion: Although plasma Gal-3 is associated with TIMP-1 and echocardiographic parameters, the diagnostic and prognostic value of Gal-3 in HFrEF is determined by the etiology of HF." @default.
• W4200221566 created "2021-12-31" @default.
• W4200221566 creator A5025802515 @default.
• W4200221566 creator A5033668453 @default.
• W4200221566 creator A5037317899 @default.
• W4200221566 creator A5043507805 @default.
• W4200221566 creator A5050211071 @default.
• W4200221566 creator A5058019993 @default.
• W4200221566 creator A5067487705 @default.
• W4200221566 creator A5068073726 @default.
• W4200221566 creator A5071230552 @default.
• W4200221566 creator A5082513643 @default.
• W4200221566 creator A5086326013 @default.
• W4200221566 creator A5088116645 @default.
• W4200221566 date "2021-12-22" @default.
• W4200221566 modified "2023-10-12" @default.
• W4200221566 title "The Diagnostic and Prognostic Value of Plasma Galectin 3 in HFrEF Related to the Etiology of Heart Failure" @default.
• W4200221566 cites W1818666302 @default.
• W4200221566 cites W1951743184 @default.
• W4200221566 cites W1969957411 @default.
• W4200221566 cites W1991935271 @default.
• W4200221566 cites W2000217815 @default.
• W4200221566 cites W2003935940 @default.
• W4200221566 cites W2029682612 @default.
• W4200221566 cites W2031170155 @default.
• W4200221566 cites W2045165072 @default.
• W4200221566 cites W2054943339 @default.
• W4200221566 cites W2056768318 @default.
• W4200221566 cites W2067973515 @default.
• W4200221566 cites W2107994885 @default.
• W4200221566 cites W2123248199 @default.
• W4200221566 cites W2141309671 @default.
• W4200221566 cites W2154815285 @default.
• W4200221566 cites W2470108555 @default.
• W4200221566 cites W2785818969 @default.
• W4200221566 cites W2805313934 @default.
• W4200221566 cites W2885871071 @default.
• W4200221566 cites W2886406646 @default.
• W4200221566 cites W2893646991 @default.
• W4200221566 cites W2899004553 @default.
• W4200221566 cites W2899214627 @default.
• W4200221566 cites W2910662478 @default.
• W4200221566 cites W2912531842 @default.
• W4200221566 cites W2912856282 @default.
• W4200221566 cites W2913819594 @default.
• W4200221566 cites W2924981418 @default.
• W4200221566 cites W2931256246 @default.
• W4200221566 cites W2937781089 @default.
• W4200221566 cites W2946419187 @default.
• W4200221566 cites W2950196821 @default.
• W4200221566 cites W2969502057 @default.
• W4200221566 cites W2972571810 @default.
• W4200221566 cites W2972716134 @default.
• W4200221566 cites W2981358333 @default.
• W4200221566 cites W2984766121 @default.
• W4200221566 cites W2996415234 @default.
• W4200221566 cites W3005261661 @default.
• W4200221566 cites W3011767668 @default.
• W4200221566 cites W43916822 @default.
• W4200221566 doi "https://doi.org/10.3389/fcvm.2021.748875" @default.
• W4200221566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35004876" @default.
• W4200221566 hasPublicationYear "2021" @default.
• W4200221566 type Work @default.
• W4200221566 citedByCount "1" @default.
• W4200221566 countsByYear W42002215662023 @default.
• W4200221566 crossrefType "journal-article" @default.
• W4200221566 hasAuthorship W4200221566A5025802515 @default.
• W4200221566 hasAuthorship W4200221566A5033668453 @default.
• W4200221566 hasAuthorship W4200221566A5037317899 @default.
• W4200221566 hasAuthorship W4200221566A5043507805 @default.
• W4200221566 hasAuthorship W4200221566A5050211071 @default.
• W4200221566 hasAuthorship W4200221566A5058019993 @default.
• W4200221566 hasAuthorship W4200221566A5067487705 @default.
• W4200221566 hasAuthorship W4200221566A5068073726 @default.
• W4200221566 hasAuthorship W4200221566A5071230552 @default.
• W4200221566 hasAuthorship W4200221566A5082513643 @default.
• W4200221566 hasAuthorship W4200221566A5086326013 @default.
• W4200221566 hasAuthorship W4200221566A5088116645 @default.
• W4200221566 hasBestOaLocation W42002215661 @default.
• W4200221566 hasConcept C126322002 @default.
• W4200221566 hasConcept C134018914 @default.
• W4200221566 hasConcept C164705383 @default.
• W4200221566 hasConcept C185592680 @default.
• W4200221566 hasConcept C204232928 @default.
• W4200221566 hasConcept C2776336362 @default.
• W4200221566 hasConcept C2778198053 @default.
• W4200221566 hasConcept C28406088 @default.
• W4200221566 hasConcept C55493867 @default.
• W4200221566 hasConcept C71924100 @default.
• W4200221566 hasConcept C72563966 @default.
• W4200221566 hasConcept C78085059 @default.
• W4200221566 hasConceptScore W4200221566C126322002 @default.
• W4200221566 hasConceptScore W4200221566C134018914 @default.
• W4200221566 hasConceptScore W4200221566C164705383 @default.
• W4200221566 hasConceptScore W4200221566C185592680 @default.
• W4200221566 hasConceptScore W4200221566C204232928 @default.
• W4200221566 hasConceptScore W4200221566C2776336362 @default.
• W4200221566 hasConceptScore W4200221566C2778198053 @default.
• W4200221566 hasConceptScore W4200221566C28406088 @default.
• W4200221566 hasConceptScore W4200221566C55493867 @default.

• next